ComboMATCH: Precision Medicine Trials

ComboMATCH is a large precision medicine initiative with a coordinated set of clinical trials evaluating new anti-cancer drug combinations in select groups of adults and children with cancer. Each trial studies the effectiveness of a specific drug combination in a select group of patients (called a phase 2 trial design). The drug combinations are either two targeted therapies or chemotherapy with a targeted drug. Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that cause them to grow, divide, and spread.

Generally, this set of trials is for patients with advanced solid tumors. However, each trial has its own patient inclusion and exclusion criteria, such as the targeted tumor gene abnormalities, type of cancer, stage of disease, prior treatment, age of the patient, etc. Therefore, patients must first enroll in the ComboMATCH Patient Registration Trial (EAY191) for a screening assessment to help determine eligibility for a treatment trial. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor.

Treatment Trials

ComboMATCH is an exciting system-wide collaboration. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN Cancer Research Group, NRG Oncology, and SWOG Cancer Research Network, lead the various treatment trials with funding from the National Cancer Institute through its National Clinical Trials Network (NCTN). Nine treatment trials are planned for ComboMATCH, opening to patient enrollment on a rolling basis.

To learn more about a particular treatment trial, click the Trial ID in the table below.
These links will open the federal trial record.

Drug Combination / Molecular Target(s)	Trial ID / Lead Group	Status
Fulvestrant hormonal therapy & binimetinib in hormone receptor positive (HR+) breast cancers with NF1 mutation or NF1 whole gene deletion	EAY191-N2 NRG Oncology	Active
Chemotherapy & binimetinib in RAS, RAF, MEK, ERK mutations	EAY191-A6 Alliance	Active
Paclitaxel chemotherapy & ipatasertib in AKT mutations	EAY191-S3 SWOG	Active
Nilotinib & paclitaxel chemotherapy in tumors previously treated with taxane chemotherapy	EAY191-E4 ECOG-ACRIN	Active
Olaparib & alpelisib in various abnormalities	EAY191-A2 Link to come Alliance	In Review
Palbociclib & binimetinib in RAS mutations	EAY191-A3 Alliance	Active
Selumetinib & DAY101	EAY191-C1 Link to come Childrens' Oncology	In Review
Selumetinib & olaparib in RAS pathway mutations	EAY191-N4 NRG Oncology	Active
Sotorasib & panitumomab in KRAS G12C mutations	EAY191-E5 ECOG-ACRIN	In Review

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Questions?

• Patients interested in learning more about ComboMATCH should start by speaking with their doctor or healthcare team or contact the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)

• Reach out to send an e-mail to the National Cancer Institute